Fullerenols Suppress Ferroptosis to Prevent Cisplatin-Induced AKI

Study Background and Research Question

Acute kidney injury (AKI) is a severe clinical syndrome characterized by a rapid decline in renal function, often triggered by nephrotoxic drugs such as cisplatin. Globally, AKI affects over 13 million people annually and accounts for approximately 1.7 million deaths, particularly in hospitalized and intensive care patients. Despite advancements in supportive care, there is currently no definitive therapy to halt or reverse AKI, largely due to its complex pathophysiology. Recent research has identified ferroptosis—a regulated, iron-dependent, non-apoptotic form of cell death driven by lipid peroxidation—as a key contributor to AKI progression. This has sparked interest in therapeutics capable of modulating ferroptosis to protect renal tissue.

Key Innovation from the Reference Study

The reference study introduces fullerenol nanoparticles as potent inhibitors of ferroptosis in the context of drug-induced AKI. Fullerenols, known for their free radical scavenging ability and biocompatibility, were systematically evaluated for their capacity to prevent cisplatin-induced renal injury. The novel insight is that fullerenols provide robust protection against ferroptosis by targeting two defining hallmarks: suppression of lipid peroxidation and mitigation of intracellular ferrous iron accumulation. This dual action distinguishes them from traditional antioxidants, which may act less specifically or effectively in ferroptosis-driven tissue injury.

Methods and Experimental Design Insights

The investigative team employed a cisplatin-induced AKI mouse model to assess the prophylactic and therapeutic efficacy of fullerenol nanoparticles. Treatment protocols involved administering fullerenols prior to cisplatin exposure, mimicking a preventive intervention. Renal function was monitored through serum creatinine, urine output, and histological analysis. To elucidate mechanisms, the study measured renal levels of malondialdehyde (a proxy for lipid peroxidation), labile iron pools, and the expression of ferroptosis-related genes and proteins, including ACSL4, ALOXE3, POR, and the system Xc⁻/GSH/GPX4 antioxidant axis. mRNA expression profiles of iron regulatory genes were also evaluated to clarify fullerenol’s impact on iron homeostasis at the molecular level.

Core Findings and Why They Matter

The study found that pre-treatment with fullerenol nanoparticles significantly attenuated cisplatin-induced AKI, as evidenced by improved renal function and reduced histopathological damage. Mechanistically, fullerenols inhibited the upregulation of ACSL4, ALOXE3, and POR—enzymes central to the propagation of lipid peroxidation during ferroptosis. Additionally, fullerenols enhanced the antioxidant capacity of renal tissue by supporting the system Xc⁻/glutathione/GPX4 axis, which is often depleted during ferroptotic cell death. Importantly, fullerenols prevented the accumulation of low-valent, redox-active iron and suppressed the transcriptional activation of iron metabolism genes, addressing both sources of ferroptotic vulnerability in kidney cells. These effects collectively offer a robust model for ferroptosis inhibition and highlight the therapeutic promise of fullerenols in AKI prevention.

Comparison with Existing Internal Articles

While the current study focuses on inhibiting ferroptosis in kidney injury, prior internal resources have primarily explored ferroptosis induction—most notably with Erastin—in the context of cancer biology. For example, the article "Erastin as a Precision Tool: Dissecting Ferroptosis and Oxidative Cell Death" discusses how Erastin, a benchmark ferroptosis inducer, selectively triggers cell death in RAS/BRAF-mutant tumor cells by disrupting redox homeostasis and glutathione metabolism. Similarly, "Erastin: Ferroptosis Inducer Unlocking Precision in Cancer Biology" and "Optimizing Ferroptosis Assays: Scenario-Based Guidance with Erastin" provide detailed protocols for using Erastin in oxidative stress assays and cancer models.

By contrast, the reference study pivots toward ferroptosis inhibition as a protective strategy in non-malignant tissue, emphasizing the importance of context in ferroptosis research. Together, these resources underscore the dual potential of ferroptosis modulators: in cancer biology, inducers like Erastin enable the study and targeting of tumor cell vulnerabilities, while in renal pathology, inhibitors like fullerenols may offer therapeutic benefit by preserving tissue integrity.

Limitations and Transferability

While the findings are promising, several limitations warrant discussion. The reference study’s results are based on a murine model of cisplatin-induced AKI, and translational relevance to human patients remains to be established. Pharmacokinetics, biodistribution, and long-term safety of fullerenol nanoparticles require further investigation. Additionally, while fullerenols outperformed conventional antioxidants in some assays, direct comparisons with clinically used ferroptosis inhibitors or established protocols were not exhaustively explored. Finally, the mechanistic focus on lipid peroxidation and iron homeostasis, though central to ferroptosis, may not capture the full spectrum of cell death pathways active in AKI. Thus, broader validation across diverse AKI etiologies and models is necessary before clinical translation.

Protocol Parameters

• Fullerenol administration (preclinical murine model): Prophylactic dosing prior to cisplatin challenge; timing and dose optimized based on pilot toxicity and efficacy screens.
• Cisplatin-induced AKI: Single intraperitoneal dose to induce renal injury, with monitoring of serum creatinine and urine output at 24-72 hours post-injection.
• Ferroptosis marker analysis: Quantification of renal malondialdehyde, labile iron, and protein/mRNA levels of ACSL4, ALOXE3, POR, and system Xc⁻/GSH/GPX4 components.
• Workflow suggestion (oxidative stress assays): For those investigating ferroptosis induction (e.g., in cancer models), validated inducers such as Erastin at 10 μM for 24 hours in engineered human tumor cells or HT-1080 fibrosarcoma cells have been widely used, as discussed in prior internal articles.

Research Support Resources

For researchers aiming to model ferroptosis-driven cell death or oxidative stress in vitro, Erastin (SKU B1524) from APExBIO is a widely used small molecule ferroptosis inducer with validated selectivity for RAS- and BRAF-mutant tumor cells. Its mechanism—modulation of the voltage-dependent anion channel and inhibition of system Xc⁻—complements approaches that seek to dissect both induction and inhibition of ferroptotic pathways. For additional workflow guidance, scenario-based discussions can be found in Optimizing Ferroptosis Assays: Scenario-Based Guidance with Erastin. Together, these tools and resources provide a robust foundation for advancing ferroptosis research across disease contexts.